Skip to content
OpenCapital
Get started

Gyre Therapeutics, Inc. GYRE Q3 2025 earnings

Reported November 7, 2025 · Before market open

Revenue$30.6MMiss by $5.7M
EPS$0.06Beat by $0.01
Revenue estimate$36.3M
EPS estimate$0.05

Next report

Aug 10, 2026 (In 1 week)
Revenue estimate$26.5M
EPS estimate-$0.08

Financials

Q3 2025

Income statement

See full
Revenue$30.6M+19.9%
Gross profit$28.9M+18.0%
Operating income$6.9M+63.6%
Net income$3.6M+221%
EPS (diluted)$0.03+200%

Balance sheet

See full
Cash & equivalents$40.4M+155%
Total debt$1.2M-35.1%
Total equity$101.9M+61.3%
Total assets$159.4M+27.3%

Cash flow

See full
Operating cash flow$4.7M—
CapEx$668.0K-3.6%
Free cash flow$4.0M—

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$677.57M-42.2%
Enterprise value$638.33M-44.9%
P/E100.4×—
P/S6.3×-4.8×

Profitability

See full
Gross margin95.5%-0.8pp
Operating margin11.2%+6.0pp
Net margin6.3%+3.3pp
FCF margin2.7%—

Returns & leverage

See full
Return on equity8.2%+4.2pp
Debt / equity0×0.0×
Current ratio6.2×+2.5×

Segments

By product

See full
Etorel$1.5M—
Contiva$1.2M—
Other Product$81.0K-60.1%

By segment

See full
Gyre Pharmaceuticals$30.6M+19.9%

Versus estimates

Revenue

Q1 2026$22.5MMiss by $9.1MQ4 2025$37.2MBeat by $1.8M
Q3 2025$30.6MMiss by $5.7M
Q2 2025$26.8MMiss by $7.5MQ1 2025$22.1MMiss by $6.6MQ4 2024$27.9MBeat by $4.4M

Diluted EPS

Q1 2026-$0.05Beat by $0.01Q4 2025$0.04Miss by $0.02
Q3 2025$0.06Beat by $0.01
Q2 2025$0.02Miss by $0.01Q1 2025$0.03In lineQ4 2024$0.01Miss by $0.03

Ask the moment Gyre Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Gyre Therapeutics, Inc. report Q3 2025 earnings?
Gyre Therapeutics, Inc. (GYRE) reported Q3 2025 earnings on November 7, 2025 before market open.
What were Gyre Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Gyre Therapeutics, Inc. reported revenue of $30.6M and eps of $0.06 for Q3 2025.
Did Gyre Therapeutics, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $36.3M by $5.7M. EPS beat the consensus estimate of $0.05 by $0.01.
How did Gyre Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 19.9% from $25.5M a year earlier and eps grew 200.0% from $0.02.
Where can I find Gyre Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-270524) and the 10-Q periodic report (0001193125-25-272383) directly on SEC EDGAR. The filing index links above go to sec.gov.